GlaxoSmithKline beats sales forecasts thanks to HIV drugs boost
Higher revenues from HIV drugs and flu vaccines have boosted quarterly sales and earnings at GlaxoSmithKline, more than offsetting a continued fall in sales for respiratory treatments. Sales rose by 9% to £6.13bn in the three months to the end of September, the third quarter of the company’s financial year. Analysts’ average forecasts were for…
Details